AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug - Pharmaceutical Technology

In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon. In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon. The epidermal growth factor receptor (EGFR) inhibitor is already approved in the US and China for a type of NSCLC. Credit: Mats Wiklund/Shutterstock.com. AstraZeneca has acquired the global rights to Dizal Pharmaceutical’s Zegfrovy (sunvozertinib), marking the drugmaker’s second venture to China in a month in search of new assets. As per the license agreement, AstraZeneca will pay an upfront fee of $600m, with a…

Source: Pharmaceutical Technology